

Zebrafish Thyroid Hormone Receptor Beta (nr1a2, TRβ) Reporter Assay System

96-well Format Assays Product # Z01101

Technical Manual (version 7.2c)

www.indigobiosciences.com

3006 Research Drive, Suite A1, State College, PA 16801, USA

Customer Service: 814-234-1919; FAX 814-272-0152 customerserv@indigobiosciences.com

Technical Service: 814-234-1919 techserv@indigobiosciences.com



Zebrafish TRβ Reporter Assay System 96-well Format Assays

I. Description

The Assay System	3
The Assay Chemistry	3
Preparation of Test Compounds	4
Considerations for Automated Dispensing	4
Assay Scheme	4
Assay Performance	5
II. Product Components & Storage Conditions	6
III. Materials to be Supplied by the User	6
IV. Assay Protocol	
• A word about Antagonist-mode assay setup	7
DAY 1 Assay Protocol	7
DAY 2 Assay Protocol	9
V. Related Products	10
VI. Limited Use Disclosures	10
APPENDIX 1: Example Scheme for Serial Dilutions	11

I. Description

The Assay System

This nuclear receptor assay system utilizes proprietary human cells engineered to provide constitutive, high-level expression of the **Zebrafish** (*Danio rerio*) **Thyroid Hormone Receptor beta** (nr1a2), a ligand-dependent transcription factor referred to herein as **zfTRβ**.

INDIGO's Reporter Cells include the luciferase reporter gene functionally linked to a TR β -responsive promoter. Thus, quantifying changes in luciferase expression in the test sample treated reporter cells provides a sensitive surrogate measure of changes in zfTR β activity.

The principal application of this assay is in the screening of test samples to quantify any functional bioactivity that they may exert against zebrafish TR β . In particular, zebrafish reporter assays are frequently used in the monitoring of environmental samples for the presence of biohazardous chemical pollutants, such as endocrine disruptors.

Reporter Cells are prepared using INDIGO's proprietary **CryoMite™** process. This cryopreservation method yields exceptional cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for cumbersome intermediate treatment steps such as spinand-rinse of cells, viability determinations, or cell titer adjustments prior to assay setup.

INDIGO's Nuclear Receptor Assays are all-inclusive assay systems. In addition to $zfTR\beta$ Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user's test samples, a reference agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate.

The Assay Chemistry

INDIGO's nuclear receptor assay kits capitalize on the extremely low background, highsensitivity, and broad linear dynamic range of bio-luminescence reporter gene technology.

Reporter Cells incorporate the cDNA encoding beetle luciferase, a 62 kD protein originating from the North American firefly (*Photinus pyralis*). Luciferase catalyzes the mono-oxidation of D-luciferin in a Mg^{+2} -dependent reaction that consumes O₂ and ATP as co-substrates, and yields as products oxyluciferin, AMP, PP_i, CO₂, and photon emission. Luminescence intensity of the reaction is quantified using a luminometer and is reported in terms of Relative Light Units (RLU's).

Assay kits feature a luciferase detection reagent specially formulated to provide stable light emission between 5 and 90+ minutes after initiating the luciferase reaction. Incorporating a 5-minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.

Preparation of Test Compounds

Small molecule compounds are typically solvated at high concentration (ideally 1,000xconcentrated) in DMSO and stored frozen as master stocks. Immediately prior to setting up an assay, the master stocks are serially diluted using **Compound Screening Medium** (**CSM**; as described in *Step 7*) to achieve the desired assay concentrations. The final concentration of total DMSO carried over into assay reactions should *never* exceed 0.4%.

NOTE: CSM is formulated to help stabilize hydrophobic test compounds in the aqueous environment. Nonetheless, high concentrations of hydrophobic test compounds diluted in CSM may lack long-term stability and/or solubility, especially if further stored at low temperatures. Hence, it is recommended that test compound dilutions are prepared in CSM immediately prior to assay setup, and are then considered to be 'single-use' reagents.

Considerations for Automated Dispensing


When processing a small number of assay plates, first carefully consider the dead volume requirement of your dispensing instrument before committing assay reagents to its setup. In essence, "dead volume" is the volume of reagent that is dedicated to the instrument; it will *not* be available for final dispensing into assay wells. The following Table provides information on reagent volume requirements, and available excesses.

Stock Reagent & Volume provided	Volume to be Dispensed (96-well plate)	Excess rgt. volume available for instrument dead volume
Reporter Cell Suspension 21 ml (prepared from kit components)	200 μl / well 19.2 ml / plate	~ 1.8 ml
LDR 12 ml (prepared from kit components)	100 μl / well 9.6 ml / plate	~ 2.4 ml

Assay Scheme

Figure 1. Assay workflow.

In brief, <u>200 µl/well</u> of Reporter Cells is dispensed into the assay plate, which is then preincubated for <u>4-6 hours</u>. Following the pre-incubation period, culture media are discarded and <u>200 µl/well</u> of the prepared treatment media are added. Following 22-24 hr incubation, treatment media are discarded and Luciferase Detection Reagent is added. The intensity of light emission (in units of 'Relative Light Units'; RLU) from each assay well is quantified using a plate-reading luminometer.



Assay Performance




Figure 2. Agonist dose-response of Zebrafish $TR\beta$ using the reference agonist L-Triiodothyronine.

zfTRβ Reporter Cells were treated with L-triiodothyronine using a 7-point concentration range generated in 3-fold decrements: 150, 50.0, 16.7, 5.56, 1.85, 0.617, and 0.206 nM, and including 'untreated' control wells (as described in Appendix 1). Luminescence/well was quantified and the average relative light units (RLU), corresponding standard deviation (SD), percent coefficient of variation (%CV) and fold-activation values were determined for each treatment concentration (n = 4). Average fold-activation +/- %CV were plotted against their respective agonist concentrations, Log10 (nM), using GraphPad Prism software. Z' was calculated as described by Zhang, *et al.* (1999)¹.

¹ Zhang JH, Chung TD, Oldenburg KR. (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen.:**4**(2), 67-73.

 $Z' = 1 - [3*(SD^{Control} + SD^{Bkg}) / (RLU^{Control} - RLU^{Bkg})]$

II. Product Components & Storage Conditions

This Zebrafish TR β Assay kit contains materials to perform assays in a single collagencoated 96-well assay plate.

Reporter cells are temperature sensitive! To ensure maximal viability the tube of Reporter Cells must be maintained at -80°C until immediately prior to the rapid-thaw procedure described in *Step 2* of this protocol.

Assay kits are shipped on dry ice. Upon receipt of the kit transfer it to -80°C storage. If you wish to first inventory the individual kit components be sure to first transfer and submerge the tube of reporter cells in dry ice.

The aliquots of Reporter Cells are provided as single-use reagents. Once thawed, reporter cells can NOT be refrozen or maintained in extended culture with any hope of retaining downstream assay performance. Therefore, extra volumes of these reagents should be discarded after assay setup.

The date of product expiration is printed on the Product Qualification Insert (PQI) enclosed with each kit.

minimum

Kit Components	Amount	Storage Temp.
 zfTRβ Reporter Cells 	1 x 2.0 mL	-80°C
Cell Recovery Medium (CRM)	2 x 10.5 mL	-20°C
Compound Screening Medium (CSM)	1 x 45 mL	-20°C
 L-Triiodothyronine, 150 μM (in DMSO) (reference agonist for TR's) 	1 x 30 µL	-20°C
Detection Substrate	1 x 6.0 mL	-80°C
Detection Buffer	1 x 6.0 mL	-20°C
 96-well, <i>collagen-coated</i> assay plate (white, sterile, cell-culture ready) 	1	-20°C

NOTE: This Assay kit contains an assay plate with wells that have been collagencoated and dried; this plate should be <u>stored frozen</u> (-20°C or colder) until use.

III. Materials to be Supplied by the User

The following materials must be provided by the user, and should be made ready prior to initiating the assay procedure:

DAY 1

- container of dry ice (used in *Step 2*)
- cell culture-rated laminar flow hood.
- 37°C, humidified 5% CO₂ incubator for mammalian cell culture.
- 37°C water bath.
- 70% alcohol wipes
- 8-channel electronic, repeat-dispensing pipettes & sterile tips
- disposable media basins, sterile.

• sterile multi-channel media basins (such as the Heathrow Scientific "Dual-Function Solution Basin"), *or* deep-well plates, *or* appropriate similar vessel for generating dilution series of reference compound(s) and test compound(s).

• Optional: clear 96-well assay plate, cell culture treated, for viewing cells on Day 2.

DAY2 plate-reading luminometer.

IV. Assay Protocol

Review the entire Assay Protocol before starting. Completing the assay requires an overnight incubation. *Steps 1-11* are performed on **Day 1**, requiring less than 2 hours of bench work and a 4 hr incubation step to complete. *Steps 12-17* are performed on **Day 2** and require less than 1 hour to complete.

A word about Antagonist-mode assay setup

Receptor inhibition assays expose the Reporter Cells to a fixed, sub-maximal concentration (typically between $EC_{50} - EC_{85}$) of a known agonist AND varying concentrations of the test compound(s) to be evaluated for antagonist activity. This assay kit includes a 150 μ M stock solution of **L-Triiodothyronine**, a potent physiological agonist of TR β that may be used to setup antagonist-mode assays. 20 nM L-Triiodothyronine typically approximates EC_{70-80} in this assay. Hence, it presents a suitable concentration of agonist to be used when screening test compounds for inhibitory activity.

Add the challenge agonist to a bulk volume of **CSM** at an $EC_{50} - EC_{85}$ concentration. This medium is then used to prepare serial dilutions of test compounds to achieve the desired respective final assay concentrations. This is an efficient and precise method of setting up antagonist assays, and it is the method presented in *Step 7b* of this protocol.

DAY 1 Assay Protocol: All steps must be performed using aseptic technique.

1.) Remove the **2 tubes** of **Cell Recovery Medium** (**CRM**) from freezer storage, thaw and equilibrate to 37° C using a water bath.

2.) Rapid Thaw of the Reporter Cells: *First*, retrieve the two tubes of **CRM** from the 37°C water bath and sanitize their outside surfaces with a 70% ethanol swab.

Second, retrieve the tube of **zfTRβ Reporter Cells** from -80°C storage, place it directly into <u>dry ice</u> and transport the cells to the laminar flow hood. When ready to begin, transfer the tube of reporter cells into a rack and, *without delay*, perform a rapid thaw of the cells by dispensing <u>9.5 ml</u> from *each* of the 2 tubes of 37°C CRM into the tube of frozen cells. Place the tube of Reporter Cells in a 37°C water bath for 5 minutes. The resulting volume of cell suspension will be **21 ml**.

3.) Retrieve the tube of Reporter Cell Suspension from the water bath and sanitize the outside surface with a 70% alcohol swab.

4.) Gently invert the tube of Reporter Cells several times to gain a homogenous cell suspension. Transfer the cell suspension into a reservoir. Using an electronic, repeat-dispensing 8chanel pipette, dispense 200 μl / well of cell suspension into all wells of the assay plate.

NOTE 4.1: If INDIGO's Live Cell Multiplex Assay is to be incorporated, a minimum of 3 'blank' wells (meaning cell-free, but containing 'CSM') must be included in the assay plate to allow quantification of fluorescence background (refer to the LCMA Technical Manual).

NOTE 4.2: Increased well-to-well variation (= increased standard deviation!) will occur if care is not taken to prevent cells from settling in the reservoir during the dispensing period. Likewise, take care to ensure precision in dispensing exact volumes across the assay plate.

NOTE 4.3: Users sometimes wish to examine the reporter cells using a microscope. If so, the extra volume of cell suspension provided with each kit may be dispensed into a clear, collagen-coated 96-well assay plate. Continue processing the clear plate in identical manner to the white assay plate.

5.) Pre-incubate reporter cells: Place the assay plate into a 37°C, \geq 85% humidity, 5% CO₂ incubator for <u>4 - 6 hours</u>.

6.) *Near the end of the 4-6 hour pre-culture period:* Remove Compound Screening Medium (CSM) from freezer storage and thaw in a 37°C water bath.

7.) Prepare the Test Compound and Reference Compound treatment media at the desired final assay concentrations: Use CSM to prepare an appropriate dilution series of the reference and test compound stocks. Prepare all treatment media at the desired final assay concentrations. In *Step 9*, the prepared treatment media will be dispensed at 200 μ l / well into the assay plate. Manage dilution volumes carefully; this assay kit provides 45 ml of CSM.

NOTE: Total DMSO carried over into assay reactions should never exceed 0.4%.

a. Agonist-mode assays. This zfTR β Assay kit includes a 150 μ M stock solution of L-Triiodothyronine, a potent reference agonist of TR β . The following 7-point treatment series, with concentrations prepared in 3-fold decrements, provides a complete dose-response: 150, 50, 16.7, 5.56, 1.85, 0.617, and 0.206 nM. APPENDIX 1 provides guidance for generating such a dilution series. Always include 'no treatment' (or 'vehicle') control wells.

~ or ~

b. Antagonist-mode assays. When setting up antagonist assays, first supplement a bulk volume of CSM with the challenge agonist **L-Triiodothyronine** to achieve an $EC_{50} - EC_{80}$ concentration (refer to "*A word about antagonist-mode assay setup*", pg. 7). The agonist-supplemented CSM is then used to generate dilutions of test compound stocks to achieve the desired series of treatment concentrations.

8.) At the end of the cell pre-incubation period, discard the culture media by ejecting it into an appropriate waste container. *Gently* tap the inverted plate onto a clean absorbent paper towel to remove residual droplets. Cells will remain tightly adhered to well bottoms.

9.) Dispense 200 μ l / well of each prepared treatment media into the assay plate.

NOTE: If well-to-well variation due to 'edge-effects' is a concern this problem *may* be mitigated by dispensing sterile liquid into the *inter-well* spaces of the assay plate. Simply remove 1 tip from the 8-chanel dispenser and dispense 100 μ l of sterile water into each of the seven inter-well spaces per column of wells.

10.) Transfer the assay plate into a 37°C, humidified 5% CO₂ incubator for <u>22 - 24 hours</u>.
 NOTE: Ensure a high-humidity (≥ 85%) environment within the cell culture incubator. This is critical to prevent the onset of deleterious "edge-effects" in the assay plate.

11.) For greater convenience on Day 2, retrieve **Detection Substrate** *and* **Detection Buffer** from freezer storage and place them in a dark refrigerator (4°C) to thaw overnight.

DAY 2 Assay Protocol: Subsequent manipulations do *not* require special regard for aseptic technique and may be performed on a bench top.

12.) *30 minutes before intending to quantify receptor activity:* remove **Detection Substrate** and **Detection Buffer** from the refrigerator and place them in a low-light area so that they may equilibrate to room temperature. Once at room temperature, gently invert each tube several times to ensure homogenous solutions.

NOTE: Do NOT actively warm Detection Substrate above room temperature. If these solutions were not allowed to thaw overnight at 4°C, a room temperature water bath may be used to expedite thawing.

13.) Set the plate-reader to "luminescence" mode. Set the instrument to perform a single 5 second "plate shake" prior to reading the first assay well. Read time may be set to 0.5 second (500 mSec) per well, *or less*.

14.) *Immediately before proceeding to Step 15*, transfer the entire volume of Detection Buffer into the vial of Detection Substrate, thereby generating a <u>12 ml</u> volume of **Luciferase Detection Reagent (LDR)**. Mix gently to avoid foaming.

15.) Following 22 - 24 hours incubation in treatment media, discard the media contents by ejecting it into an appropriate waste container. *Gently* tap the inverted plate onto a clean absorbent paper towel to remove residual droplets. Cells will remain tightly adhered to well bottoms.

16.) Add $\underline{100 \ \mu l}$ of **LDR** to each well of the assay plate. Allow the assay plate to rest at room temperature for at least <u>5 minutes</u> following the addition of LDR. Do not shake the assay plate during this period.

17.) Quantify luminescence.

V. Related Products

Human TRβ Assay Products			
Product No.	Product Descriptions		
IB01101-32	Human TRβ Reporter Assay 3x 32 assays in 8-well strips (96-well plate format)		
IB01101	Human TRβ Reporter Assay 1x 96-well format assay		
IB01102	Human TRβ Reporter Assay 1x 384-well format assays		
Bulk volumes of Assay Reagents may be custom manufactured to accommodate any scale of HTS. Please Inquire.			
Zebrafish TRβ Assay Products			
Z01101-32	Zebrafish TRβ Reporter Assay 3x 32 assays in 8-well strips (96-well plate format)		
Z01101	Zebrafish TRβ Reporter Assay 1x 96-well format assay		
Panel of Human TR Assays			
IB01201-48P	Human TR α and TR β Reporter Assay PANEL 48 assays each, 8 well strips (96-well plate format)		

LIVE Cell Multiplex (LCM) Assay		
LCM-01	Reagent volumes sufficient to perform 96 Live Cell Assays in 1x96-well, or 2x48-well, or 3x32-well assay plate formats	
LCM-05	Reagent in 5x bulk volume to perform 480 Live Cell Assays contained in 5 x 96-well assay plates	
LCM-10	Reagent in 10x bulk volume to perform 960 Live Cell Assays contained in 10 x 96-well assay plates	

Please refer to INDIGO Biosciences website for updated product offerings.

www.indigobiosciences.com

VI. Limited Use Disclosures

Products commercialized by INDIGO Biosciences, Inc. are for RESEARCH PURPOSES ONLY – not for therapeutic, diagnostic, or contact use in humans.

"CryoMite" is a Trademark TM of INDIGO Biosciences, Inc. (State College, PA, USA).

Product prices, availability, specifications, claims and technical protocols are subject to change without prior notice. The Technical Manual accompanying assay kit box will always be the most currently updated version.

Copyright © INDIGO Biosciences, Inc. (State College, PA, USA). All rights reserved.

APPENDIX 1

Example scheme for the serial dilution of L-Triiodothyronine reference agonist, and the setup of a $zfTR\beta$ dose-response assay.

